Barclays Maintains Underweight on Celldex Therapeutics, Raises Price Target to $24

Benzinga · 2d ago
Barclays analyst Etzer Darout maintains Celldex Therapeutics (NASDAQ:CLDX) with a Underweight and raises the price target from $21 to $24.